Defcort 6 mg (Deflazacort)

Defcort 6 mg is a prescription corticosteroid tablet manufactured by Macleods Pharmaceuticals Pvt Ltd. It belongs to the class of synthetic glucocorticoids known as deflazacort, a molecule derived from prednisolone that exhibits potent anti‑inflammatory, anti‑allergic, and immunosuppressant properties. The medication is presented in a strip containing ten tablets, each delivering a precise dose of 6 mg of active ingredient. This formulation is intended for oral administration and is indicated specifically for the treatment of severe allergic conditions that require a systemic corticosteroid response. Clinicians consider Defcort 6 mg when topical agents or antihistamines are insufficient to control acute or chronic inflammatory manifestations of allergy.

What is Defcort 6 mg?

Defcort 6 mg contains deflazacort as its active pharmaceutical ingredient. Deflazacort functions as a pro‑drug that is metabolized in the liver to an active metabolite with high affinity for glucocorticoid receptors located in various immune cells. Binding to these receptors modulates gene transcription pathways that regulate inflammation, cytokine production, and cellular immune responses. The 6 mg strength provides a moderate systemic dose that is sufficient to suppress excessive immune activity in severe allergic reactions while minimizing the risk of overt steroid excess when used according to clinical guidelines. Because it is a corticosteroid, Defcort must be prescribed after a thorough evaluation of the patient’s medical history, current health status, and potential drug interactions.

Uses and Benefits

The therapeutic uses of Defcort 6 mg extend to a variety of severe allergic presentations. Its primary indication is the management of acute urticaria and angioedema that do not respond adequately to first‑generation antihistamines. Additionally, the tablet is employed in the treatment of chronic allergic rhinitis, severe asthma exacerbations triggered by allergic factors, and certain autoimmune skin conditions where an immune‑mediated component is evident. The benefits observed with Defcort include rapid reduction of swelling, itching, and erythema, restoration of normal airway patency, and improvement in quality of life for patients experiencing debilitating allergic symptoms. Compared with higher‑dose steroid regimens, the 6 mg formulation offers a favorable balance between efficacy and safety, especially when the treatment course is limited to a few weeks and followed by a gradual taper.

• Rapid symptom attenuation, often within the first 24 hours
• Improved control of refractory allergic manifestations
• Convenient once‑dayly oral dosing that enhances adherence
• Lower systemic exposure than many traditional corticosteroids, supporting long‑term tolerability
• Compatibility with combination therapy using antihistamines or leukotriene modifiers

How It Works

The pharmacodynamic action of deflazacort centers on its ability to suppress the inflammatory cascade that drives allergic disease. Upon ingestion, deflazacort is absorbed from the gastrointestinal tract and undergoes hepatic conversion to its active form, which then binds to intracellular glucocorticoid receptors. This receptor‑ligand complex translocates to the nucleus and influences the expression of numerous genes involved in immune regulation. Key outcomes include inhibition of phospholipase A2, decreased production of prostaglandins and leukotrienes, and reduced migration of neutrophils and eosinophils to sites of inflammation. Consequently, the inflammatory mediators that cause swelling, pain, and tissue damage are markedly diminished, leading to clinical relief of allergic signs. The drug also stabilizes mast cells, further limiting the release of histamine and other mediators that exacerbate allergic responses.

From a pharmacokinetic perspective, deflazacort exhibits moderate plasma protein binding and a half‑life of approximately 2–3 hours, allowing for once‑daily administration. It is primarily metabolized in the liver via enzymatic pathways that are shared with several other medications, underscoring the importance of reviewing a patient’s full medication list before initiation.

Dosage Guidelines

Dosage of Defcort 6 mg is individualized based on the severity of the allergic condition, patient age, body weight, and comorbid health issues. In adult patients with severe acute urticaria, a typical initial regimen may involve one tablet daily for a period of 5 to 7 days, followed by a tapering schedule that reduces the dose by 6 mg every 2–3 days until discontinuation, provided that clinical improvement is sustained. For chronic allergic rhinitis, a lower maintenance dose may be prescribed, such as one tablet every other day, with close monitoring for side effects. Pediatric dosing is weight‑based; a common approach is 0.15 mg per kilogram of body weight per day, not exceeding the adult maximum of 6 mg per day. Patients should be instructed to take the tablet with food to reduce gastrointestinal irritation, and to swallow it whole without crushing or chewing. It is essential that individuals do not adjust the dose on their own and that any missed dose be discussed with a healthcare professional rather than doubled.

Side Effects

All corticosteroid therapies carry a risk of adverse effects, and Defcort 6 mg is no exception. Most side effects are mild and reversible upon discontinuation, but patients should remain vigilant for both common and rare reactions. The most frequently reported adverse events include increased appetite, mild weight gain, and transient gastrointestinal discomfort such as heartburn or nausea. Some individuals experience alterations in blood glucose levels, which may necessitate adjustments in diabetes management. Mood changes, including irritability or mild anxiety, have also been documented. Less common but clinically significant effects comprise hypertension, fluid retention, and, in rare cases, cardiac arrhythmias. Prolonged use may lead to osteoporosis, cataracts, or adrenal suppression, emphasizing the need for periodic bone density assessments and blood pressure monitoring. Should any side effect become severe or persist beyond the expected duration, immediate medical consultation is recommended.

• Appetite increase leading to modest weight gain
• Elevated blood glucose, especially in diabetic patients
• Gastrointestinal upset, including dyspepsia
• Sleep disturbances or mood swings
• Rare but serious cardiovascular effects such as hypertension

Warnings and Precautions

Prior to prescribing Defcort 6 mg, clinicians should conduct a comprehensive assessment to identify contraindications and risk factors. Patients with active infections, particularly viral or fungal diseases, should be cautioned that corticosteroids can mask fever and other early signs of illness, potentially delaying appropriate treatment. Individuals with a history of peptic ulcer disease, uncontrolled diabetes, hypertension, or severe psychiatric disorders require careful monitoring. Long‑term therapy mandates regular evaluation of bone mineral density, lipid profiles, and ophthalmologic health to preempt steroid‑related complications. Abrupt discontinuation of the medication is discouraged; instead, a gradual taper under medical supervision helps prevent adrenal insufficiency and rebound inflammation. Pregnant or lactating women should only use Defcort if the anticipated benefit justifies the potential risk, as determined by a qualified physician. Finally, drug interactions with immunosuppressants, anticoagulants, or certain antihypertensive agents may alter therapeutic outcomes, making a thorough medication reconciliation essential.

For additional authoritative guidance, refer to the U.S. Food and Drug Administration (FDA) prescribing information and the National Institutes of Health (NIH) drug information portal.

Frequently Asked Questions

What conditions can Defcort 6 mg treat?

Defcort 6 mg is indicated for severe allergic reactions such as acute urticaria, angioedema, and chronic allergic rhinitis when systemic corticosteroid therapy is required. It may also be used in the management of severe asthma exacerbations with an allergic trigger and certain autoimmune skin conditions that involve an immune‑mediated component.

How quickly does Defcort relieve allergic symptoms?

Most patients notice a reduction in itching, swelling, and redness within 2 to 4 hours after the first dose, with maximal symptom relief typically observed by the end of the day. The rapid onset makes Defcort a preferred option for acute, debilitating allergic episodes.

Can Defcort be taken together with antihistamines or other allergy medications?

Yes, Defcort is often co‑administered with antihistamines, leukotriene receptor antagonists, or topical corticosteroids to achieve comprehensive control of allergic inflammation. However, the combination should be supervised by a healthcare provider to monitor for potential drug interactions and to ensure appropriate dosing.

Is long‑term use of Defcort safe, and what monitoring is required?

Long‑term therapy can be safe when administered at the lowest effective dose and accompanied by regular clinical monitoring. Recommended assessments include blood pressure checks, blood glucose monitoring, bone density scans, and periodic ophthalmic examinations. Adjustments to the treatment plan are made based on these findings to mitigate steroid‑related complications.

Where can I purchase authentic Defcort 6 mg tablets?

Authentic Defcort 6 mg tablets should be obtained from licensed pharmacies or authorized online retailers that comply with local regulatory standards. The manufacturer’s official website, Macleods Pharmaceuticals, provides a directory of verified distributors. Additionally, verification of the product’s registration can be performed through the FDA Drug Registration database.

Related Products

• Defcort (Deflazacort)
• Defcort 12 mg (Deflazacort)
• Defcort 18 mg (Deflazacort)
• Defcort 24 mg (Deflazacort)
• Defcort 30 mg (Deflazacort)
• Megalis Tablet (Tadalafil)
• Megalis 20 mg (Tadalafil)
• Omnacortil (Prednisolone)
• Omnacortil 5mg (Prednisolone)
• Omnacortil 10 mg (Prednisolone)
• Omnacortil 20 mg DT (Dispersible Tablets)
• Omnacortil 30 mg (Prednisolone)